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Objective To explore the rate of reported congenital abnormalities in infants exposed to 
antiretroviral therapy (ART) in utero. 
Design Comprehensive national surveillance study in the United Kingdom and Ireland.  
Methods Births to diagnosed HIV-infected women are reported to the National Study of 
HIV in Pregnancy and Childhood. Infants born between 1990 and 2007 were included. 
Results The rate of reported major and minor congenital abnormality was 2.8% 
(232/8242) overall, and there was no significant difference by timing of ART exposure: 
2.8% (14/498) in unexposed infants, 2.7% (147/5427) following second or third 
trimester exposure, and 3.1% (53/1708) following first trimester exposure (p=0.690). 
There was no difference in abnormality rates by class of ART exposure in the first 
trimester (p=0.363), and no category of abnormality was significantly associated with 
timing of ART, although numbers in these groups were small. There was no increased 
risk of abnormalities in infants exposed to efavirenz (p=0.672) or didanosine (p=0.816) 
in the first trimester. 
Conclusions These findings, based on a large, national, unselected population provide 
further reassurance that ART in utero does not pose a major risk of fetal anomaly.  
 
 





Introduction   
 
Antiretroviral therapy (ART) has had a major impact on reducing the risk of mother-to-
child transmission of HIV,
1
 and the majority of HIV-infected women in the UK and 
Ireland now receive ART at some time in pregnancy.
2
 Nevertheless, there are concerns 
about potential teratogeneticity, particularly since around a quarter of HIV-infected 
women conceived on treatment in recent years.
1
  
Large-scale observational studies have so far detected no overall increase in congenital 
abnormality rates associated with first trimester ART exposure.
3-5
 However, an 
increased abnormality rate in 353 infants exposed to didanosine in the first trimester 
(4.5%, 95% confidence interval [CI]: 2.6%-7.3%) compared with a population rate of 
2.7%, was recently detected through international prospective monitoring by the 
Antiretroviral Pregnancy Registry,
6
 and a significantly increased prevalence of 
hypospadias following first trimester zidovudine exposure (7/382), compared with later 
or no exposure (2/892), has been reported from the Women and Infants Transmission 
Study (WITS).
4
 There have also been case reports of neural tube defects in infants 
exposed to efavirenz in the first trimester.
7;8
 
HIV infection in pregnant women and their children has been monitored in the UK and 
Ireland since the late 1980s, through a unique, population-based surveillance scheme.
2
 
We previously investigated the association between in utero ART exposure and 
congenital abnormalities in over 3100 infants born between 1990 and 2003.
9
 In this 
updated analysis, including four additional years of surveillance data, we report on over 
8500 children born between 1990 and 2007.  
 





Active surveillance of obstetric and paediatric HIV in the UK and Ireland is carried out 
through the National Study of HIV in Pregnancy and Childhood (NSHPC). Full 
methods are described elsewhere.
1;2
 This analysis includes all infants (live born, 
stillborn, twins and triplets) born between 1990 and 2007 in the UK and Ireland to 
women diagnosed before delivery, and reported by June 2008. Information on maternal 
demographic characteristics, pregnancy outcome, delivery, perinatal details, type and 
timing of ART is routinely collected through the NSHPC. Congenital abnormalities are 
reported by both obstetric and paediatric respondents, mostly within the first few weeks 
of life. Most variables are obtained from both sources, except for timing of ART and 
maternal clinical status (AIDS or HIV-related symptoms in pregnancy), which are 
collected only from obstetric respondents.  
Timing of ART exposure in pregnancy was classified as early if therapy was started 
before conception or up to 12 completed weeks of gestation, and late if started after 12 
weeks. Class of antiretroviral regimen was categorised as nucleoside reverse 
transcriptase inhibitors (NRTI) only, or according to inclusion of non-nucleoside 
reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), or both NNRTIs and 
PIs. Four infants in the PI group were also exposed to fusion inhibitors in the first 
trimester (none had an abnormality reported).  
Congenital abnormalities were classified using the World Health Organisation’s 
International Classification of Diseases.
10
 For infants with multiple abnormalities 
reported (n=19), only the main abnormality was included in the analysis. Detailed 
  
6 
information on whether abnormalities were major or minor was not routinely collected; 
however, in order to assess the prevalence of major abnormalities, the following were 
classified as minor: polydactyly, malformed ear, abnormalities of the feet, minor mouth 
abnormalities, undescended testes, accessory nipple, spinal hairy patch, strawberry nevi, 
skin tag, and subclinical sub-ependymal cysts. 
Data were managed in a Microsoft Access 2002 database and analysed using Stata 10.0 
(Stata Corporation, College Station, TX). Congenital abnormality rates and 95% CIs 
were calculated. Because of specific concerns, abnormality rates were also calculated 
for infants exposed to efavirenz or didanosine in early pregnancy, as was the rate of 
hypospadias in male infants. Differences in rates were assessed using χ2  and Fisher’s 
exact tests. Logistic regression models were developed to adjust for potential 
confounders, including maternal ethnicity, age, injecting drug use (as the reported route 







Maternal and pregnancy characteristics and ART 
Altogether 8576 infants were reported, including 92 stillbirths and 288 twins or triplets. 
Information was available from both paediatric and obstetric sources for 79% of infants, 
but the remainder were reported only through the obstetric (10%) or paediatric (11%) 
scheme. Information on congenital abnormality was available for 96.1% (8242/8576) of 
infants. Of these, most were born between 2000 and 2007 (Table 1). Three quarters 
were born to black African women, and median maternal age at delivery was 30 years 
    
7 
(interquartile range [IQR]: 26.3-33.8 years). Median age at last report was 6 months 
(IQR: 3-15 months). 
Information on timing of ART exposure was missing for 7.4% (609/8242) of infants, 
mostly (88%, 538/609) because reports were only obtained from paediatric respondents 
who were not asked to provide this information. Less than a quarter of infants (22.4%) 
had early in utero exposure (Table 1), mostly to NNRTI-containing regimens (52.9%).  
 
Congenital abnormalities  
Altogether 232 infants out of 8242 were reported to have at least one congenital 
abnormality (2.8%, 95% CI: 2.5%-3.2%), a quarter of whom had only minor 
abnormalities (59/232). The abnormality rate excluding minor defects was 2.1% (95% 
CI: 1.8%-2.4%). Infants with missing information on congenital abnormality (n=334) 
were more likely than those with information to be preterm or of low birth weight (25% 
vs. 15%) or to have mothers who were untreated in pregnancy (30% vs. 7%) (p<0.001), 
but not more likely to have early ART exposure (15% vs. 22%, p=0.478). 
Abnormality rates were lower in infants born to black African mothers than in those 
born to white mothers, and higher among infants whose mothers were symptomatic 
(Table 1). Infants with abnormalities were more likely to be delivered prematurely and 
to be of low birth weight, and girls had a lower reported rate than boys.  
There was no significant difference in the unadjusted abnormality rate by ART 
exposure: 2.8% in unexposed infants, 2.7% in those with late exposure, and 3.1% in 
those with early exposure (p=0.690) (Table 1). After adjusting for potential confounders 
(maternal ethnicity, age at delivery, injecting drug use and clinical status) neither late 
  
8 
(adjusted odds ratio [AOR]=0.96, 95% CI: 0.54-1.71, p=0.889) nor early ART exposure 
(AOR=1.01, 95% CI: 0.54-1.88, p=0.972) was significantly associated with congenital 
abnormality (n=7179). AORs were similar to the unadjusted ORs presented in Table 1, 
including for maternal ethnic group and clinical status. 
Class of ART was reported for 99.4% (1697/1708) of infants exposed in the first 
trimester and was not significantly associated with congenital abnormality (p=0.363) 
(Table 1). After adjusting for maternal ethnicity, age, injecting drug use and clinical 
status, infants exposed to PIs showed no significant difference in congenital abnormality 
rates compared with those exposed to NNRTIs (AOR=1.09, 95% CI: 0.58-2.07 
p=0.789), nor did those exposed to NRTIs only (AOR=1.94, 95% CI: 0.84-4.50, 
p=0.123),  or NNRTI- and PI-containing regimens (AOR=1.15, 95% CI: 0.34-3.92, 
p=0.823) (n=1679). Infants exposed only to NRTIs were more likely than those exposed 




A total of 220 infants were exposed to efavirenz, 205 (93.2%) in early pregnancy; of 
those exposed early, 2.4% (5/205) had abnormalities reported (undescended testes 
[n=2], hip dislocation [n=2], hypertrophic pyloric stenosis). This did not differ 
significantly from the rate in infants with first trimester exposure to drugs other than 
efavirenz (3.2%, 48/1503, p=0.672). There were 284 exposures to didanosine, 174 
(61.3%) in the first trimester; of those infants with early exposure, 3.4% (6/174) had 
abnormalities reported (Down’s syndrome, heart defect [n=2], hydronephrosis, jejunal 
atresia, foot abnormality); this did not differ significantly from the rate for other first 
trimester ART exposures (3.1%, 47/1534, p=0.816). There were no abnormalities 
    
9 
reported in infants only exposed to efavirenz (n=15) or didanosine (n=110) later in 
pregnancy. 
The most commonly reported abnormality types were musculoskeletal (40/232), limb 
(32/232), heart/circulatory (30/232), and genital organs (22/232; 12 hypospadias, 9 
undescended testes, 1 ambiguous genitalia) (Table 2). No category of abnormality was 
significantly associated with timing of ART (Table 2). Of the 12 cases of hypospadias, 
all were in infants exposed to zidovudine-containing regimens (0.18%, 12/6711, versus 
0%, 0/792, exposed to zidovudine-sparing regimens, p=0.262). Timing of ART was 
reported for 11 of these infants: two had early exposure (2/1708, 0.12%; or 2/856 boys, 
0.23%), and nine late (9/5427, 0.17%; or 9/2693 boys, 0.33%), with no statistically 
significant difference between the two groups (p=1.00). 
 
Terminated pregnancies (not included in overall analysis) 
Twenty-one congenital abnormalities were reported in 549 terminated pregnancies 
(1990-2007): anencephaly (n=4), Down’s syndrome (n=5), other chromosomal anomaly 
(n=3), exomphalos, enlarged cerebral ventricles, cleft lip/palate, hydronephrosis, bowel 
abnormality, heart defect, spina bifida, achondroplasia, and renal agenesis. These 21 
terminations were carried out between 12 and 30 weeks gestation, and only five were in 
women who were on treatment (HAART) in early pregnancy. The overall abnormality 






An overall congenital abnormality rate of 2.8% (2.1% excluding minor defects) was 
observed in this unselected population of around 8200 infants. This is consistent with 
national population estimates of 2-3% for major abnormalities in England and 2.2% for 
Europe as a whole (calculated from EUROCAT data tables, 1980-2006).
11;12
  
In common with a number of other large-scale observational studies,
3-5
 we did not 
detect any significant association between rate of reported congenital abnormalities and 
type or timing of ART in pregnancy; nor did we detect any significant increase in the 
overall abnormality rate following early exposure to efavirenz (n=205) or didanosine 
(n=174). The number of reported cases of hypospadias was small (n=12), and rates 
were similar following early or late ART exposure. The overall excess of abnormalities 
in boys was mainly accounted for by genital abnormalities, all of which were in boys. 
The increased abnormality rates in symptomatic and white women were reported 
previously
9
, but reasons remain unclear.  
While these results are reassuring, the overall rate is likely to be a minimum estimate. In 
particular, abnormalities not apparent at birth might have been under-reported, either 
because the birth was only notified through the obstetric scheme, or because diagnosis 
occurred after the last report. However, reporting of most major abnormalities apparent 
in the first few weeks of life is likely to be relatively complete. Although ascertainment 
of early terminations in HIV-infected women is incomplete
2
, terminations carried out 
after a congenital anomaly scan are likely to be well reported.  
Infants missing information on congenital abnormality were more likely to be 
premature, a factor associated with congenital abnormalities; however, they were no 
more likely to have early ART exposure that those with information provided. Finally, 
although information on maternal ethnicity, age, injecting drug use and clinical status 
    
11 
was available, data on other potential confounders such as maternal smoking and diet 
during pregnancy, concurrent infections, and non-HIV medication were not.  
Although this analysis included over 8200 infants (1700 with early ART exposure), at 
least 350 exposures to any specific drug would be required to detect a 2-fold increase in 
overall risk with 80% power, and even larger numbers would be required to detect an 
association with a particular type of abnormality. Nevertheless, these results provide 
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  n % n  % OR  (95% CI) p-value 
Time period (n=8242)        
≤1999 833 10.1 31 3.7 1.00   
2000-2007 7409 89.9 201 2.7 0.72 (0.49-1.06) 0.970 
Maternal characteristics         
Ethnic origin (n=8171)        
White * 1285 15.7 46 3.6 1.00   
Black African ** 6244 76.4 162 2.6 0.72 (0.51-1.00) 0.051 
Black Other 326 4.0 13 4.0 1.12 (0.60-2.10) 0.726 
Other 316 3.9 10 3.2 0.88 (0.44-1.76) 0.719 
Age at delivery (n=8184)        
<25 years 1471 18.0 40 2.7 1.00   
25-34 years 5154 63.0 147 2.9 1.05 (0.74-1.50) 0.786 
≥ 35 years 1559 19.0 43 2.8 1.01 (0.66-1.57) 0.948 
HIV exposure group (n=8242)        
Other risk *** 7876 95.6 219 2.8 1.00   
Injecting drug use 366 4.4 13 3.6 1.29 (0.73-2.28) 0.384 
Clinical status (n=7235)        
No HIV-related symptoms 6451 89.2 174 2.7 1.00   
HIV-related symptoms/AIDS 784 10.8 32 4.1 1.54 (1.05-2.25) 0.029 
Infant characteristics        
Sex (n=8202)        
Male  4123 50.3 137 3.3 1.00   
Female 4079 49.7 91 2.2 0.66 (0.51-0.87) 0.003 
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Gestational age (n=8056)        
≥37 weeks 6874 85.3 182 2.6 1.00   
<37 weeks 1182 14.7 47 4.0 1.52 (1.10-2.11) 0.012 
Birth weight (n=7153)        
≥2.5 kg 6067 84.8 158 2.6 1.00   
<2.5 kg 1086 15.2 45 4.1 1.62 (1.15-2.27) 0.005 
Treatment characteristics        
Timing of ART exposure(n=7633)       
Not treated in pregnancy 498 6.5 14 2.8 1.00   
Late (2nd/3rd trimester) 5427 71.1 147 2.7 0.96 (0.55-1.68) 0.893 
Early (1st trimester) 1708 22.4 53 3.1 1.11 (0.61-2.01) 0.739 
Treatment class in 1st trimester (n=1697)      
NRTI only 148 8.7 8 5.4 2.08 (0.92-4.72) 0.080 
NNRTI   898 52.9 24 2.7 1.00   
PI  553 32.6 17 3.1 1.16 (0.61-2.17) 0.654 
NNRTI & PI 98 5.8 3 3.1 1.15 (0.34-3.89) 0.822 
 
* 82.5% (998/1210) of white women were born in the UK or Ireland; ** 97.6% (6012/6162) of 
black African women were born in sub-Saharan Africa; *** Other risk includes heterosexual, 
‘from area of high HIV prevalence’ and vertical transmission. 
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Table 2.  Reported category of congenital abnormality by timing of ART exposure 
          Timing of ART exposure 
Type of abnormality  Total 








  n  (%) n  (%) n  (%) n  (%) n  (%) p value ** 
Nervous system 17 0.21 16 0.21 1 0.20 11 0.20 4 0.23 0.767 
Ear, face, neck & eye 5 0.06 4 0.05 0 0.00 3 0.06 1 0.06 1.000 
Heart & circulatory 30 0.36 25 0.33 0 0.00 16 0.29 9 0.53 0.144 
Respiratory system 4 0.05 3 0.04 1 0.20 2 0.04 0 0.00 1.000 
Cleft palate/lip 7 0.08 7 0.09 1 0.20 5 0.09 1 0.06 1.000 
Digestive system 18 0.22 18 0.24 1 0.20 11 0.20 6 0.35 0.262 
Genital organs 22 0.27 19 0.25 3 0.60 11 0.20 5 0.29 0.594 
Urinary system 20 0.24 19 0.25 1 0.20 11 0.20 7 0.41 0.163 
Musculoskeletal 40 0.49 38 0.50 2 0.40 27 0.50 9 0.53 0.846 
Limbs 32 0.39 30 0.39 3 0.60 23 0.42 4 0.23 0.279 
Integument 11 0.13 10 0.13 0 0.00 7 0.13 3 0.18 0.474 
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Chromosomal 21 0.25 20 0.26 1 0.20 16 0.29 3 0.18 0.594 
Other & unspecified anomalies 2 0.02 2 0.03 0 0.00 1 0.02 1 0.06 0.397 
Type not specified 3 0.04 3 0.04 0 0.00 3 0.06 0 0.00 1.000 
Total congenital abnormalities  232 2.81 214 2.80 14 2.81 147 2.71 53 3.10  
Total infants 8242   7633   498   5427   1708     
 
* Excludes 18 infants with abnormalities for whom information on timing of treatment was not available 





 (1)  Townsend CL, Cortina-Borja M, Peckham CS, de RA, Lyall H, Tookey PA. 
Low rates of mother-to-child transmission of HIV following effective pregnancy 
interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 
22(8):973-981. 
 (2)  Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in 
management and outcome of pregnancies in HIV-infected women in the UK and 
Ireland, 1990-2006. BJOG 2008. 
 (3)  European Collaborative Study. Does highly active antiretroviral therapy increase 
the risk of congenital abnormalities in HIV-infected women? J Acquir Immune 
Defic Syndr 2005; 40(1):116-118. 
 (4)  Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M et al. Assessment of 
birth defects according to maternal therapy among infants in the Women and 
Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44(3):299-305. 
 (5)  Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K 
et al. Assessing the risk of birth defects associated with antiretroviral exposure 
during pregnancy. Am J Obstet Gynecol 2004; 191(3):985-992. 
 (6)  Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy 
Registry International Interim Report for 1 January 1989 through 31 July 2008.  
2008. Available at: http://www.apregistry.com/. [Accessed 10 November 2008]. 
  
19 
 (7)  De Santis M, Cavaliere AF, Caruso A, Villa P, Tamburrini E, Cauda R et al. 
Hemangiomas and other congenital malformations in infants exposed to 
antiretroviral therapy in utero. JAMA 2004; 291(3):305. 
 (8)  Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. 
Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 
2002; 16(2):299-300. 
 (9)  Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral 
therapy and congenital abnormalities in infants born to HIV-1-infected women 
in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 
2006; 42(1):91-94. 
 (10)  World Health Organization. International Statistical Classification of Diseases 
and Related Health Problems, 1989 Revision. Geneva: World Health 
Organization; 1992. 
 (11)  EUROCAT. EUROCAT Special Report. The environmental causes of 
congenital anomalies: a review of the literature [online].  2004. Available at: 
www.eurocat.ulster.ac.uk/pubdata. [Accessed 10 November 2008]. 
 (12)  EUROCAT. 1980-2006 Prevalence Data Tables.  2008. Available at: 
www.eurocat.ulster.ac.uk/pubdata/tables.html. [Accessed 10 November 2008]. 
 
